Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review

  • ID: 4189010
  • SWOT Analysis
  • 68 pages
  • GlobalData
  • Mylan N.V.
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Endo International Plc
  • GlaxoSmithKline Plc
  • MallInckrodt Plc
  • Merck & Co Inc
  • Sandoz Inc
  • MORE
Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV Key Recent Developments

Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
Feb 26, 2018: Mylan launches Saugella in India
Nov 20, 2017: Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Endo International Plc
  • GlaxoSmithKline Plc
  • MallInckrodt Plc
  • Merck & Co Inc
  • Sandoz Inc
  • MORE
Section 1 - About the Company
  • Mylan NV - Key Facts
  • Mylan NV - Key Employees
  • Mylan NV - Key Employee Biographies
  • Mylan NV - Major Products and Services
  • Mylan NV - History
  • Mylan NV - Company Statement
  • Mylan NV - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Mylan NV - Business Description
  • Business Segment: Europe
  • Overview
  • Performance
  • Key Stats
  • Business Segment: North America
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Rest of World
  • Overview
  • Performance
  • Key Stats
  • R&D Overview
  • Mylan NV - SWOT Analysis
  • SWOT Analysis - Overview
  • Mylan NV - Strengths
  • Mylan NV - Weaknesses
  • Mylan NV - Opportunities
  • Mylan NV - Threats
  • Mylan NV - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Mylan NV, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
  • Feb 26, 2018: Mylan launches Saugella in India
  • Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
  • Nov 20, 2017: Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference
  • Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange
  • Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded
  • Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
  • Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint
  • Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer
  • Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Mylan NV, Key Facts
  • Mylan NV, Key Employees
  • Mylan NV, Key Employee Biographies
  • Mylan NV, Major Products and Services
  • Mylan NV, History
  • Mylan NV, Other Locations
  • Mylan NV, Subsidiaries
  • Mylan NV, Key Competitors
  • Mylan NV, Ratios based on current share price
  • Mylan NV, Annual Ratios
  • Mylan NV, Annual Ratios
  • Mylan NV, Annual Ratios
  • Mylan NV, Interim Ratios
  • Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Mylan NV, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Mylan NV, Performance Chart (2013 - 2017)
  • Mylan NV, Ratio Charts
  • Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Teva Pharmaceutical Industries Ltd
  • Sandoz Inc
  • Par Pharmaceutical Holdings Inc
  • Merck & Co Inc
  • MallInckrodt Plc
  • GlaxoSmithKline Plc
  • Endo International Plc
  • Allergan Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll